1580504-68-2

Upstream product

• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 
• 1580504-67-1 (5-(4-(2-methoxyethoxy)-2-methylphenyl)pyridin-2-yl)methanol 
• 14472-14-1 4-bromo-3-methylphenol 
• 947410-56-2 1-bromo-4-(2-methoxyethoxy)-2-methylbenzene 

Downstream Products

• 1580504-69-3 2-((5-(4-(2-methoxyethoxy)-2-methylphenyl)pyridin-2-yl)methoxy)nicotinic acid 
• 1580504-59-1 2-((5-(4-(2-methoxyethoxy)-2-methylphenyl)pyridin-2-yl)methoxy)-N-methylnicotinamide 
• 1580504-60-4 2-((5-(4-(2-methoxyethoxy)-2-methylphenyl)pyridin-2-yl)methoxy)-N,N-dimethylnicotinamide 
• 1580504-61-5 (3-hydroxypyrrolidin-1-yl)(2-((5-(4-(2-methoxyethoxy)-2-methylphenyl)pyridin-2-yl)methoxy)pyridin-3-yl)methanone 
• 1580504-62-6 N-(2-hydroxyethyl)-2-((5-(4-(2-methoxyethoxy)-2-methylphenyl)pyridin-2-yl)methoxy)nicotinamide 
• 1580504-63-7 2-((5-(4-(2-methoxyethoxy)-2-methylphenyl)pyridin-2-yl)methoxy)-N-(1-methylpiperidin-4-yl)nicotinamide 

Relevant academic research and scientific papers

Biarylmethoxy nicotinamides as novel and specific inhibitors of mycobacterium tuberculosis

A whole cell based screening effort on a focused library from corporate collection resulted in the identification of biarylmethoxy nicotinamides as novel inhibitors of M. tuberculosis (Mtu) H37Rv. The series exhibited tangible structure-activity relationships, and during hit to lead exploration, a cellular potency of 100 nM was achieved, which is an improvement of >200-fold from the starting point. The series is very specific to Mtu and noncytotoxic up to 250 μM as measured in the mammalian cell line THP-1 based cytotoxicity assay. This compound class retains its potency on several drug sensitive and single drug resistant clinical isolates, which indicate that the compounds could be acting through a novel mode of action.